Cargando…

Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma

Solute carrier family 39, member 1 (SLC39A1) is a member of the zinc-iron permease family and located to the cell membrane, acting as a zinc uptake transporter. However, the clinical impacts of SLC39A1 in early-stage hepatocellular carcinoma (EHCC) have not been defined. In this research, we compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qinglin, Pan, Jiadong, An, Fangmei, Nie, He, Zhan, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806984/
https://www.ncbi.nlm.nih.gov/pubmed/34615436
http://dx.doi.org/10.1080/21655979.2021.1987131
_version_ 1784643589351931904
author Zhang, Qinglin
Pan, Jiadong
An, Fangmei
Nie, He
Zhan, Qiang
author_facet Zhang, Qinglin
Pan, Jiadong
An, Fangmei
Nie, He
Zhan, Qiang
author_sort Zhang, Qinglin
collection PubMed
description Solute carrier family 39, member 1 (SLC39A1) is a member of the zinc-iron permease family and located to the cell membrane, acting as a zinc uptake transporter. However, the clinical impacts of SLC39A1 in early-stage hepatocellular carcinoma (EHCC) have not been defined. In this research, we compared the differential expression of SLC39A1 in EHCC and normal tissues based on tissue microarray, and the clinical significance of SLC39A1 in EHCC was evaluated as well. Compared with adjacent tissues, SLC39A1 was remarkably decreased in paired EHCC tissues. Besides, decreased SLC39A1 expression was significantly associated with several clinic-pathological features and serum biochemical indicators. Furthermore, Kaplan-Meier analysis exhibited that both overall survival (OS) and relapse-free survival (RFS) of patients with low expression of SLC39A1 were notably poorer than that of patients with high expression. Moreover, Cox regression analyses revealed that low expression of SLC39A1 was an independent prognostic factor for OS in patients with EHCC. Subgroup analysis also revealed beneficiary populations benefiting from the prognostic evaluation using SLC39A1 expression. Collectively, we summarized that downregulated expression of SLC39A1 is a worse prognostic factor for patients with EHCC, which can be used as a promising diagnostic and prognostic biomarker for EHCC.
format Online
Article
Text
id pubmed-8806984
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88069842022-02-02 Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma Zhang, Qinglin Pan, Jiadong An, Fangmei Nie, He Zhan, Qiang Bioengineered Research Paper Solute carrier family 39, member 1 (SLC39A1) is a member of the zinc-iron permease family and located to the cell membrane, acting as a zinc uptake transporter. However, the clinical impacts of SLC39A1 in early-stage hepatocellular carcinoma (EHCC) have not been defined. In this research, we compared the differential expression of SLC39A1 in EHCC and normal tissues based on tissue microarray, and the clinical significance of SLC39A1 in EHCC was evaluated as well. Compared with adjacent tissues, SLC39A1 was remarkably decreased in paired EHCC tissues. Besides, decreased SLC39A1 expression was significantly associated with several clinic-pathological features and serum biochemical indicators. Furthermore, Kaplan-Meier analysis exhibited that both overall survival (OS) and relapse-free survival (RFS) of patients with low expression of SLC39A1 were notably poorer than that of patients with high expression. Moreover, Cox regression analyses revealed that low expression of SLC39A1 was an independent prognostic factor for OS in patients with EHCC. Subgroup analysis also revealed beneficiary populations benefiting from the prognostic evaluation using SLC39A1 expression. Collectively, we summarized that downregulated expression of SLC39A1 is a worse prognostic factor for patients with EHCC, which can be used as a promising diagnostic and prognostic biomarker for EHCC. Taylor & Francis 2021-10-21 /pmc/articles/PMC8806984/ /pubmed/34615436 http://dx.doi.org/10.1080/21655979.2021.1987131 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Zhang, Qinglin
Pan, Jiadong
An, Fangmei
Nie, He
Zhan, Qiang
Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title_full Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title_fullStr Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title_full_unstemmed Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title_short Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
title_sort decreased slc39a1 (solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806984/
https://www.ncbi.nlm.nih.gov/pubmed/34615436
http://dx.doi.org/10.1080/21655979.2021.1987131
work_keys_str_mv AT zhangqinglin decreasedslc39a1solutecarrierfamily39member1expressionpredictsunfavorableprognosisinpatientswithearlystagehepatocellularcarcinoma
AT panjiadong decreasedslc39a1solutecarrierfamily39member1expressionpredictsunfavorableprognosisinpatientswithearlystagehepatocellularcarcinoma
AT anfangmei decreasedslc39a1solutecarrierfamily39member1expressionpredictsunfavorableprognosisinpatientswithearlystagehepatocellularcarcinoma
AT niehe decreasedslc39a1solutecarrierfamily39member1expressionpredictsunfavorableprognosisinpatientswithearlystagehepatocellularcarcinoma
AT zhanqiang decreasedslc39a1solutecarrierfamily39member1expressionpredictsunfavorableprognosisinpatientswithearlystagehepatocellularcarcinoma